In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the most common primary liver tumors. Dr. Katz is joined by Venu Pillarisetty, M.D., Professor of Hepatopancreatobiliary Surgery at the University of Washington and Medical Director of Continuous Performance Improvement at Seattle Cancer Care Alliance and Karie Runcie, M.D., Assistant Professor of Medicine at Columbia University Herbert Irving Comprehensive Cancer Center
The PERIO-02 trial is evaluating SD-101, an investigational toll-like receptor 9 (TLR9) agonist, delivered intravascularly by the TriNav Infusion System using the Pressure-Enabled Drug Delivery (PEDD) method of administration. The study objective is to understand the ability of this platform to overcome two major challenges of treatment: immune response suppression and ineffective drug delivery.
Steven C. Katz, MD, FACS
Dr. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Board. In September 2020, Dr. Katz became Chief Medical Officer of TriSalus. During his academic career, he led a translational immunotherapy program focused on regional delivery of CAR-T cells for liver tumors and a basic science lab dedicated to studying liver immune cell biology. Dr. Katz continues to practice as a surgical oncologist in Rhode Island, is an Associate Professor of Surgery, and serves on the editorial boards of several scientific journals. Dr. Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award. He completed his general surgery residency at the New York University Medical Center and fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. His clinical expertise is in liver surgery, pancreatic surgery, sarcoma, and melanoma.
Venu G. Pillarisetty, MD, FACS
Dr. Pillarisetty is a Professor of Hepatopancreatobiliary Surgery at the University of Washington and Medical Director of Continuous Performance Improvement at Seattle Cancer Care Alliance. He attended Columbia University College of Physicians and Surgeons and did his General Surgery residency at the University of Massachusetts. He completed fellowships in Tumor Immunology and Surgical Oncology at Memorial Sloan-Kettering Cancer Center prior to joining the faculty at the University of Washington. He is a highly specialized surgical oncologist who treats patients with pancreatic cancer and other diseases involving the pancreas, using both open and minimally invasive techniques.
Karie Runcie, M.D.
Dr. Runcie is an Assistant Professor of Medical Oncology at Columbia University Herbert Irving Comprehensive Cancer Center specialized in treating hepatobiliary cancers. She received her B.A. in Biological Sciences and Sociology from Rice University and earned her medical degree from Albert Einstein College of Medicine. Dr. Runcie then completed her residency training at New York-Presbyterian Weill Cornell Medical Center and a fellowship in Hematology and Medical Oncology at New York-Presbyterian Columbia University Irving Medical Center where she was chosen as Chief Fellow. She has a particular interest in clinical trials and the development of novel immune therapies for the treatment of hepatobiliary tumors.